A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
Mesoblast’s achievement in winning approval for its Ryoncil drug in the US in December heralds the arrival of a new class of ...
A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.
TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...
While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...
The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.
New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!